The biggest ecommerce in the world with >$1T GMV and the leading cloud services provider in the accelerating China market at 14x Fwd PE.
Natan's fair value: ~$162 (+32%)
2) $TransMedics Group, Inc.(TMDX)$
Stock is down 15% from recent high and remains very undervalued.
The company is innovating the transplants market and they plan to achieve 10k transplants in 2028.
Natan's fair value: ~$174 (+45%)
One of the fastest growing ecommerces in the world trading at 8X EV/FCF.
Management proved many times its ability to deliver impressive growth and profitability in one of the most competitive market in the world.
Natan's fair value: ~$173 (+36%)
4) $Regeneron Pharmaceuticals(REGN)$
An extraordinary founder-led biotech, focused on internal R&D for nearly 35 years.
The stock, down 50% from its all-time high, does not remotely reflect Regeneron’s true value and potential.
Natan's fair value: ~$786 (+33%)
5) $Vertex Pharmaceuticals(VRTX)$
This is my favorite biotech.
The 100B Boston giant dominates the monopoly in CF drugs and patent of Trikafta expires in 2037 only.
Perfect balance sheet and expected double digit EPS growth going forward.
Natan's fair value: ~$475 (+20%)
One of the most successful gold miner priced at only 5X Fwd PE.
Despite a strong +60% YTD, B2 remains severely undervalued compared to peers and considering the many catalyst ahead.
Natan's fair value: ~$6 (+51%)
7) $PROCEPT BioRobotics(PRCT)$
A growth company in robotic surgery that is gaining traction with Aquablation as a leading treatment for BPH.
The stock has struggled recently, and a 7× price-to-sales multiple doesn't reflect the growth potential.
Natan's fair value: ~$57 (+39%)
They developed a platform to manufacturing mRNA vaccines, the pipeline includes 45 drugs (9 phase 3 and 16 phase 2) in 4 therapeutic areas.
I think that market is too focused on the short term prospects of this company.
Natan's fair value: ~$60 (+122%)
The sector is very competitive but PayPal is catching up with innovation under the new CEO.
Moroever PayPal is cannibalizing its own shares with huge buybacks.
At 13X Fwd PE is extremely attractive.
Natan's fair value: ~$107 (+53%)
The largest company in the U.S. private health insurance sector.
I believe the recent sell-offs are exaggerated, and the company still holds a strong competitive advantage thanks to its integration.
Natan's fair value: ~$364 (+19%)
For whom haven't open CBA can know more from below:
🏦 Open a CBA today and enjoy privileges of up to SGD 20,000 in trading limit with 0 commission. Trade SG, HK, US stocks as well as ETFs unlimitedly!
Find out more here:
Comments